Report Overview

The South Korea glucagon like peptide-1 (GLP-1) receptor agonist market size stood at around USD xx billion in 2019 and is projected to reach xx billion by 2028, exhibiting a CAGR of around 6.7 % during the forecast period.

GLP-1 receptor agonist medicines, also called incretin mimetics, are a type of incretin-based medicine fortype 2 diabetes. This type of medicine is based on the action of hormones called incretins, which help control how the pancreas works. One type of incretin, called GLP-1, causes your pancreas to produce more insulin after you eat and helps keep blood glucose levels in the normal range. These medicines copy, or mimic, the action of GLP-1 made by human body. The effects of GLP-1 only last for a few minutes, but GLP-1 receptor agonists medicines can last for hours or days.



Market Drivers

Increasing prevalence of diabetes in Korea is expected to drive the market. The increase in the diabetic population over the years is due to the overall effect of individual-level factors, like the increasing median age of the population and health factors, including increasing rates of obesity and changing lifestyle among people. Pharmaceutical companies are making innovations in terms of formulations, improved bioavailability, combination therapies, and route of administration which will further promote the market growth. Although, product failure is expected to limit the growth of market.